Treatment of painful diabetic peripheral neuropathy

Prosthetics and Orthotics International

Volumn 39, Issue 1, 2015, Pages 17-28

  Rosenberg, Casandra J ^a   Watson, James C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Diabetes; Diabetic peripheral neuropathy; Neuropathy; Painful neuropathy

Indexed keywords

AMITRIPTYLINE; BACLOFEN; CAPSAICIN; GABAPENTIN; KETAMINE; LEVACECARNINE; LIDOCAINE; MENTHOL; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TAPENTADOL; THIOCTIC ACID; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; ANALGESIC AGENT;

ACUPUNCTURE; ANTINOCICEPTION; BLEEDING; COGNITIVE DEFECT; COGNITIVE THERAPY; COMPULSION; CONSTIPATION; DIABETIC NEUROPATHY; DIZZINESS; DROWSINESS; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG MECHANISM; DRUG MEGADOSE; ENDOCRINE DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HEART ARRHYTHMIA; HUMAN; HYPERALGESIA; HYPERHIDROSIS; INSOMNIA; INTOXICATION; MYOCLONUS; NAUSEA; NEUROMODULATION; NEUROPATHIC PAIN; ORTHOSTATIC HYPOTENSION; PAINFUL DIABETIC PERIPHERAL NEUROPATHY; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRURITUS; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; SEIZURE THRESHOLD; SEROTONIN SYNDROME; SKIN IRRITATION; SYSTEMATIC REVIEW (TOPIC); TRANSCUTANEOUS NERVE STIMULATION; URINE RETENTION; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA; ANALGESIA; DIABETIC NEUROPATHIES; ELECTROSTIMULATION THERAPY; PROCEDURES;

ANALGESICS; COGNITIVE THERAPY; DIABETIC NEUROPATHIES; ELECTRIC STIMULATION THERAPY; GUIDELINES AS TOPIC; HUMANS; PAIN MANAGEMENT; QUALITY OF LIFE;

EID: 84927736824     PISSN: 03093646     EISSN: 17461553     Source Type: Journal    
DOI: 10.1177/0309364614542266     Document Type: Review

References (113)

1. Centers for Disease Control and Prevention. National diabetes facts sheet, national estimates and general information on diabetes and pre-diabetes in the United States. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
2. Argoff CE, Cole BE, Fishbain DA, et al. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 2006; 81: S3-S11.
3. Partanen J, Niskanen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1955; 333: 89-94.
4. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-824.
5. Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care 2004; 27: 1591-1597.
6. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009; 35: 206-213.
7. Berger A, Dukes EM and Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004; 5: 143-149.
8. Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003; 26: 1790-1795.
9. Benbow SJ, Wallymahmed ME and MacFarlane IA. Diabetic peripheral neuropathy and quality of life. QJM 1998; 91: 733-737.
10. Galer BS, Gianas A and Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47: 123-128.
11. Sadosky A, Schaefer C, Mann R, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes 2013; 6: 79-92.
12. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1997; 73: 123-139.
13. Dworkin RH. Inclusion criteria, http://www.acc.co.nz/for-providers/clinical-best-practice/interventional-painmanagement/interventions/intervention-index/WCM1-034233 (2013, accessed 27 March 2014).
14. O'Connor AB and Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009; 122: S22-S32.
15. Davies HT, Crombie IK, Lonsdale M, et al. Consensus and contention in the treatment of chronic nerve-damage pain. Pain 1991; 47: 191-196.
16. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289-305.
17. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17: 1113-e88.
18. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85: S3-S14.
19. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007; 12: 13-21.
20. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011; 76: 1758-1765.
21. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1995; 122: 561-568.
22. Fullerton B, Jeitler K, Seitz M, et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014; 2: CD009122.
23. Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163: 2433-2445.
24. Santoro D, Satta E, Messina S, et al. Pain in end-stage renal disease: a frequent and neglected clinical problem. Clin Nephrol 2013; 79(Suppl. 1): S2-S11.
25. Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 149-158.
26. Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009; 374: 1252-1261.
27. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis 2001; 3: 53-62.
28. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352: 1324-1334.
29. Furukawa TA, McGuire H and Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 2002; 325: 991.
30. Prochazka AV, Kick S, Steinbrunn C, et al. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004; 164: 2229-2233.
31. Micromedex 2.0 (Amitriptyline Hydrochloride) Available at: http://www.micromedexsolutions.com/micromedex2/librarian/ND-T/evidencexpert/ND-PR/evidencexpert/CS/54AC7A/ND-AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/AEFE69/ND-PG/evidencexpert/ND-B/evidencexpert/ND-P/evidencexpert/PFActionId/evidencexpert. DoIntegratedSearch?Search Term=amitriptyline (accessed 30 April 2014).
32. Micromedex 2.0 (Nortriptyline Hydrochloride) Available at: http://www.micromedexsolutions.com/micromedex2/librarian/ND-T/evidencexpert/ND-PR/evidencexpert/CS/B42175/ND-AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/56E6AD/ND-PG/evidencexpert/ND-B/evidencexpert/ND-P/evidencexpert/PFActionId/evidencexpert. DoIntegratedSearch?Search Term=nortriptyline (accessed 30 April 2014).
33. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidencebased guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22(4): 343-396.
34. Waring WS. Clinical use of antidepressant therapy and associated cardiovascular risk. Drug Healthc Patient Saf 2012; 4: 93-101.
35. Cohen HW, Gibson G and Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000; 108: 2-8.
36. US Food and Drug Administration. Medication guide: antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions, http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ucm100211.pdf
37. US Food and Drug Administration. Medication guide: Pamelor, http://www.fda.gov/downloads/Drugs/Drug Safety/ucm088671.pdf (accessed 27 April 2014).
38. Morello CM, Leckband SG, Stoner CP, et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159: 1931-1937.
39. Marks DM, Shah MJ, Patkar AA, et al. Serotonin norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol 2009; 7: 331-336.
40. Saarto T and Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007; 4: CD005454.
41. Lunn MP, Hughes RA and Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 2014; 1: CD007115.
42. Brecht S, Courtecuisse C, Debieuvre C, et al. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry 2007; 68: 1707-1716.
43. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med 2006; 119(2): 113-136.
44. US Food and Drug Administration. Medication guide: Cymbalta http://www.fda.gov/downloads/Drugs/Drug Safety/ucm088579.pdf (accessed 28 April 2014).
45. Kaur H, Hota D, Bhansali A, et al. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care 2011; 34: 818-822.
46. Rose MA and Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002 May; 57: 451-462.
47. Fehrenbacher JC, Taylor CP and Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003; 105: 133-141.
48. US Food and Drug Administration. Medication guide: Lyrica, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM152825.pdf (accessed 28 April 2014).
49. US Food and Drug Administration. Medication guide: Neurontin, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM229208.pdf (accessed 28 April 2014).
50. Jensen MP, Chodroff MJ and Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007; 68: 1178-1182.
51. Pollack MH, Matthews J and Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 1998; 155: 992-993.
52. Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004; 63: 2104-2110.
53. Wong MC, Chung JW and Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ 2007; 335: 87.
54. Afilalo M and Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician 2013; 16: 27-40.
55. Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999; 83: 85-90.
56. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50: 1842-1846.
57. Janssen Pharmaceuticals. NDA 200533: NUCYNTA ER Tablets (Opioid analgesics), http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm270224.pdf (accessed 25 August 2011).
58. Raffa RB, Buschmann H, Christoph T, et al. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother 2012; 13: 1437-1449.
59. Niesters M, Proto PL, Aarts L, et al. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J Anaesth 2014; 113: 148-156.
60. Kosten TR and George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect 2002; 1: 13-20.
61. National Survey on Drug Use and Health (NSDUH) is an annual survey sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA), http://oas.samhsa.gov
62. Savage SR. Assessment for addiction in pain-treatment settings. Clin J Pain 2002; 18: S28-S38.
63. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008; 11: S105-S120.
64. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004; 28: 497-504.
65. Dwyer JP, Jayasekera C and Nicoll A. Analgesia for the cirrhotic patient: a literature review and recommendations. J Gastroenterol Hepatol. Epub ahead of print 18 February 2014. DOI: 10.1111/jgh.12560.
66. US Food and Drug Administration. NUCYNTA (tapentadol) immediate-release oral tablets: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER), October 2013, http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm233891.htm
67. US Food and Drug Administration. NUCYNTA ER FDA risk evaluation and mitigation strategy, approved 25 August 2011, http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm270224.pdf
68. US Food and Drug Administration. Ultram ER prescribing information, updated September 2006, http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/021692s005s007lbl.pdf
69. Gimbel JS, Richards P and Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003; 60: 927-934.
70. Watson CP, Moulin D, Watt-Watson J, et al. Controlledrelease oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105: 71-78.
71. Rowbotham MC, Twilling L, Davies PS, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003; 348: 1223-1232.
72. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011; 27: 151-162.
73. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002; 59: 1015-1021.
74. Nuckols TK, Anderson L, Popescu I, et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med 2014; 160: 38-47.
75. Mayo Clinic. Capsaicin (topical route): side effects, http://www.mayoclinic.org/drugs-supplements/capsaicin-topicalroute/side-effects/drg-20062561 (accessed 27 April 2014).
76. Qutenza. Healthcare professional resources: safety information, http://www.qutenza.com/ (accessed 27 April 2014).
77. Simpson DM, Gazda S, Brown S, et al. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage 2010; 39: 1053-1064.
78. Derry S, Sven-Rice A, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2013; 2: CD007393.
79. Cummins TR. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol 2007; 582(Pt 1): 11.
80. Endo Pharmaceuticals, Inc. LIDODERM lidocaine patch 5%, http://www.endo.com/File%20Library/Products/Prescribing%20Information/LIDODERM-prescribing-information.html (accessed 30 April 2014).
81. Barbano RL, Herrmann DN, Hart-Gouleau S, et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004; 61: 914-918.
82. Baron R, Mayoral V, Leijon G, et al. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin 2009; 258: 1677-1687.
83. Proudfoot CJ, Garry EM, Cottrell DF, et al. Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr Biol 2006; 16: 1591-1605.
84. Davies SJ, Harding LM and Baranowski AP. A novel treatment of postherpetic neuralgia using peppermint oil. Clin J Pain 2002; 18: 200-202.
85. Wasner G, Naleschinski D, Binder A, et al. The effect of menthol on cold allodynia in patients with neuropathic pain. Pain Med 2008 9; 354-358.
86. Lynch ME, Clark AJ, Sawynok J, et al. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology 2005; 103: 140-146.
87. Lynch ME, Clark AJ, Sawynok J, et al. Topical amitriptyline and ketamine in neuropathic pain syndromes: an openlabel study. J Pain 2005; 6: 644-649.
88. Gewandter JS, Mohile SG, Heckler CE, et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer. Epub ahead of print 16 February 2014. DOI: 10.1007/s00520-014-2158-7.
89. Barton DL, Wos EJ, Qin R, et al. A double-blind, placebocontrolled trial of a topical treatment for chemotherapyinduced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 2011; 19: 833-841.
90. Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160-1167.
91. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29: 2365-2370.
92. Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a meta-analysis. Diabet Med 2004; 21: 114-121.
93. Scafidi S, Fiskum G, Lindauer SL, et al. Metabolism of acetyl-l-carnitine for energy and neurotransmitter synthesis in the immature rat brain. J Neurochem 2010; 114: 820-831.
94. Evans JD, Jacobs TF and Evans EW. Role of acetyl-l-carnitine in the treatment of diabetic peripheral neuropathy. Ann Pharmacother 2008; 42: 1686-1691.
95. Sima AA. Acetyl-l-carnitine in diabetic polyneuropathy: experimental and clinical data. CNS Drugs 2007; 21: 13-23.
96. Sima AA, Calvani M, Mehra M, et al. Acetyl-l-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 2005; 28: 89-94.
97. Abuaisha BB, Costanzi JB and Boulton AJ. Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long-term study. Diabetes Res Clin Pract 1998; 39: 115-121.
98. Jiang H, Shi K, Li X, et al. Clinical study on the wrist-ankle acupuncture treatment for 30 cases of diabetic peripheral neuritis. J Tradit Chin Med 2006; 26: 8-12.
99. Tong Y, Guo H and Han B. Fifteen-day acupuncture treatment relieves diabetic peripheral neuropathy. J Acupunct Meridian Stud 2010; 3: 95-103.
100. Dubinsky RM and Miyasaki J. Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74: 173-176.
101. Kumar D and Marshall HJ. Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care 1997; 20: 1702-1705.
102. Forst T, Nguyen M, Forst S, et al. Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device. Diabetes Nutr Metab 2004; 17: 163-168.
103. Glombiewski JA, Hartwich-Tersek J and Rief W. Two psychological interventions are effective in severely disabled, chronic back pain patients: a randomised controlled trial. Int J Behav Med 2010; 17: 97-107.
104. Hoffman BM, Papas RK, Chatkoff DK, et al. Meta-analysis of psychological interventions for chronic low back pain. Health Psychol 2007; 26: 1-9.
105. Holroyd KA, O'Donnell FJ, Stensland M, et al. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. JAMA 2001; 285: 2208-2215.
106. Otis JD, Sanderson K, Hardway C, et al. A randomized controlled pilot study of a cognitive-behavioral therapy approach for painful diabetic peripheral neuropathy. J Pain 2013; 14: 475-482.
107. Daousi C, Benbow SJ and MacFarlane IA. Electrical spinal cord stimulation in the long-term treatment of chronic painful diabetic neuropathy. Diabet Med 2005; 22: 393-398.
108. Tesfaye S, Watt J, Benbow SJ, et al. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet 1996; 348: 1698-1701.
109. Kumar K, Toth C and Nath RK. Spinal cord stimulation for chronic pain in peripheral neuropathy. Surg Neurol 1996; 46: 363-369.
110. Huntoon MA and Burgher AH. Ultrasound-guided permanent implantation of peripheral nerve stimulation (PNS) system for neuropathic pain of the extremities: original cases and outcomes. Pain Med 2009; 10: 1369-1377.
111. Medtronic Targeted Drug Delivery. Indications, safety, and warnings, http://professional.medtronic.com/pt/neuro/idd/ind/ (accessed 27 April 2014).
112. Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 2004; 11: 3029-3040.
113. Deer TR, Smith HS, Cousins M, et al. Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery. Pain Physician 2010; 13: E175-E213.